ASXL1 and intrahepatic cholangiocarcinoma: For example, mutations in genes like ASXL1, BCOR, STAG2 or ZRSR2 can be used for AML classification in correspondence with the ICC guidelines from 2022 and are essential for risk-stratification and prognostic decisions in AML patients according to the European LeukemiaNet [3].